147 related articles for article (PubMed ID: 20117197)
1. Novel milk-based oral formulations: proof of concept.
Charkoftaki G; Kytariolos J; Macheras P
Int J Pharm; 2010 May; 390(2):150-9. PubMed ID: 20117197
[TBL] [Abstract][Full Text] [Related]
2. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics.
Cheney ML; Weyna DR; Shan N; Hanna M; Wojtas L; Zaworotko MJ
J Pharm Sci; 2011 Jun; 100(6):2172-81. PubMed ID: 21491441
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi A; Jamali F
Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548
[TBL] [Abstract][Full Text] [Related]
4. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
5. Stability and physicochemical characterization of novel milk-based oral formulations.
Kytariolos J; Charkoftaki G; Smith JR; Voyiatzis G; Chrissanthopoulos A; Yannopoulos SN; Fatouros DG; Macheras P
Int J Pharm; 2013 Feb; 444(1-2):128-38. PubMed ID: 23340327
[TBL] [Abstract][Full Text] [Related]
6. Improved absorption of meloxicam via salt formation with ethanolamines.
Han HK; Choi HK
Eur J Pharm Biopharm; 2007 Jan; 65(1):99-103. PubMed ID: 16919925
[TBL] [Abstract][Full Text] [Related]
7. The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel.
Chang JS; Tsai YH; Wu PC; Huang YB
Drug Dev Ind Pharm; 2007 Sep; 33(9):984-9. PubMed ID: 17891585
[TBL] [Abstract][Full Text] [Related]
8. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
[TBL] [Abstract][Full Text] [Related]
9. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
Bachhav YG; Patravale VB
Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
[TBL] [Abstract][Full Text] [Related]
10. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
Vivancos M; Barker J; Engbers S; Fischer C; Frederick J; Friedt H; Rybicka JM; Stastny T; Banse H; Cribb AE
Can Vet J; 2015 Jul; 56(7):730-6. PubMed ID: 26130835
[TBL] [Abstract][Full Text] [Related]
12. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization.
Ah YC; Choi JK; Choi YK; Ki HM; Bae JH
Int J Pharm; 2010 Jan; 385(1-2):12-9. PubMed ID: 19833177
[TBL] [Abstract][Full Text] [Related]
13. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.
Weyna DR; Cheney ML; Shan N; Hanna M; Zaworotko MJ; Sava V; Song S; Sanchez-Ramos JR
Mol Pharm; 2012 Jul; 9(7):2094-102. PubMed ID: 22642304
[TBL] [Abstract][Full Text] [Related]
14. A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design.
Aboelwafa AA; Fahmy RH
Pharm Dev Technol; 2012; 17(1):1-14. PubMed ID: 20550483
[TBL] [Abstract][Full Text] [Related]
15. Cyclodextrin-based oral dissolving films formulation of taste-masked meloxicam.
Samprasit W; Akkaramongkolporn P; Kaomongkolgit R; Opanasopit P
Pharm Dev Technol; 2018 Jun; 23(5):530-539. PubMed ID: 29103353
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence studies of two brands of meloxicam tablets in healthy Pakistani volunteers.
Hasan SM; Shoaib MH; Hassan F; Rehman IU
Pak J Pharm Sci; 2009 Apr; 22(2):199-204. PubMed ID: 19339233
[TBL] [Abstract][Full Text] [Related]
17. Formulation optimization of transdermal meloxicam potassium-loaded mesomorphic phases containing ethanol, oleic acid and mixture surfactant using the statistical experimental design methodology.
Huang CT; Tsai CH; Tsou HY; Huang YB; Tsai YH; Wu PC
J Microencapsul; 2011; 28(6):508-14. PubMed ID: 21726123
[TBL] [Abstract][Full Text] [Related]
18. Effect of solubility enhancement on nasal absorption of meloxicam.
Horváth T; Ambrus R; Völgyi G; Budai-Szűcs M; Márki Á; Sipos P; Bartos C; Seres AB; Sztojkov-Ivanov A; Takács-Novák K; Csányi E; Gáspár R; Szabó-Révész P
Eur J Pharm Sci; 2016 Dec; 95():96-102. PubMed ID: 27260088
[TBL] [Abstract][Full Text] [Related]
19. Bovine serum albumin-meloxicam nanoaggregates laden contact lenses for ophthalmic drug delivery in treatment of postcataract endophthalmitis.
Zhang W; Zu D; Chen J; Peng J; Liu Y; Zhang H; Li S; Pan W
Int J Pharm; 2014 Nov; 475(1-2):25-34. PubMed ID: 25158220
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows.
Malreddy PR; Coetzee JF; Kukanich B; Gehring R
J Vet Pharmacol Ther; 2013 Feb; 36(1):14-20. PubMed ID: 22372845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
